Lessons Learned
DISEASE, METASTATIC RENAL CELL CARCINOMA
The recommended dose of cabozantinib in combination with avelumab is 40 mg daily.Avelumab and cabozantinib achieved disease control rate and objective response rate of 92% and 50%, respectively, in untreated metastatic renal cell carcinoma.The combination therapy of avelumab and cabozantinib is well tolerated with manageable side effects.